Clinical Trial Update: A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs [Phase 3]

View source ↗

Summary

This document details a Phase 3 clinical trial evaluating injection TQB2102 for HER2 IHC3+ advanced colorectal cancer that progressed after standard therapies; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• TQB2102

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Conditions: HER2 IHC3+ Advanced Colorectal Cancer | Phase 3 | Status: NOT_YET_RECRUITING